This provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts.
The ICCI is an international centre of excellence for the advancement of cannabis and cannabinoid treatments.
The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators.
Zelda’s managing director Dr Richard Hopkins said: “We’re honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programs.